Patients manifesting with both HIV and cancer face a complex treatment challenge. The interplay between these two diseases can lead to unique patient manifestations and present significant obstacles in achieving optimal results. Pharmacological synergies offer a promising avenue for improving the management of this vulnerable patient segment. By s